SpringWorks Therapeutics Total Liabilities 2019-2022 | SWTX

SpringWorks Therapeutics total liabilities from 2019 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
SpringWorks Therapeutics Annual Total Liabilities
(Millions of US $)
2021 $30
2020 $19
2019 $13
2018 $5
SpringWorks Therapeutics Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $29
2021-12-31 $30
2021-09-30 $29
2021-06-30 $24
2021-03-31 $20
2020-12-31 $19
2020-09-30 $13
2020-06-30 $10
2020-03-31 $9
2019-12-31 $13
2019-09-30 $11
2019-06-30 $0
2019-03-31 $0
2018-12-31
2018-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.838B $0.035B
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00